Bruker AXS Wins Prestigious R&D 100 Award For Innovative VANTEC(TM)-2000 X-ray Detector Used in Materials Science Research
"Since its introduction, the VANTEC-2000 has dramatically boosted the performance of X-ray diffraction (XRD) detectors for materials research. It combines low noise, high sensitivity, excellent spatial resolution and dynamic range with real-time data acquisition. This even allows for snapshot and movie mode acquisition in a virtually maintenance-free detector, that is unrivalled in the XRD marketplace," stated Uwe Preckwinkel, the Bruker AXS U.S. XRD Product Manager.
“provides a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year”
Unlike older XRD detector technologies, the VANTEC-2000 measures the two-dimensional X-ray diffraction pattern from a sample. The result allows for the calculation of a wide variety of physical parameters in a broad range of sample types. Because of its unique capability to detect individual photons at up to 2 million counts per second, the detector is ideal for the analysis of weakly and/or strongly scattering samples - including smallest sample traces, single crystals, epitaxial thin films, coatings, rocks, polymers, metals, steel, wood, plastics, liquids, nanomaterials and more.
The award, selected by an independent panel of judges and the editors of R&D Magazine, "provides a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year," explained the magazine's Editor-in-Chief, Tim Studt.
About Bruker Biosciences (NASDAQ: BRKR)
Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis by X-ray crystallography, X-ray diffraction and X-ray fluorescence. Its systems, which have particular application in the life science, materials science and nanotechnology research fields, provide customers with high-throughput capabilities to determine small molecule and protein structures, or to characterize and determine the composition and properties of advanced and nano-materials. For more information, please visit www.bruker-axs.com.
Any statements contained in this press release with respect to Bruker AXS or Bruker BioSciences or their businesses that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.